Yelena Tropsha serves as Vice President - Commercial Access of the Company. rior to joining our company, Dr. Tropsha was a Vice President of Research and Development, Clinical Research and Office of Medical Affairs at Coloplast from July 2017 to December 2017. From July 2015 to July 2017, Dr. Tropsha was a Vice President of Research and Development, Clinical Research and Regulatory Affairs at Coloplast. From September 2008 to July 2015, she was a Vice President of Research and Development and Clinical Research at Coloplast. Dr. Tropsha earned her M.S. in Chemistry and her Ph.D. in Polymer Science from Moscow State University in Russia.
As the Vice President - Commercial Access of Neuronetics Inc, the total compensation of Yelena Tropsha at Neuronetics Inc is $738,195. There are 4 executives at Neuronetics Inc getting paid more, with Daniel Guthrie having the highest compensation of $1,937,180.
Yelena Tropsha is 59, she's been the Vice President - Commercial Access of Neuronetics Inc since 2018. There are 5 older and 7 younger executives at Neuronetics Inc. The oldest executive at Neuronetics Inc is Wilfred Jaeger, 64, who is the Independent Director.
Yelena's mailing address filed with the SEC is C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN, PA, 19355.
Over the last 6 years, insiders at Neuronetics Inc have traded over $9,582,393 worth of Neuronetics Inc stock and bought 1,499,267 units worth $4,708,316 . The most active insiders traders include Capital Llc Cannell, Ronald Hunt, eGlenn P Muir. On average, Neuronetics Inc executives and independent directors trade stock every 20 days with the average trade being worth of $21,199. The most recent stock trade was executed by Glenn P Muir on 5 September 2024, trading 25,000 units of STIM stock currently worth $20,000.
with neurostar advanced therapy, neuronetics, inc., is the market leader in transcranial magnetic stimulation technology for the treatment of major depressive disorder. based in malvern, pa, we are a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. we are the first company to have a non-systemic and non-invasive depression treatment cleared by the fda for patients who have not benefited from prior antidepressant medication. neuronetics markets neurostar advanced therapy throughout the united states and select markets around the world. if you have questions or comments about neurostar, please e-mail us at customersupport@neuronetics.com. for u.s. phone support, please call us at (877) 600-7555, for international customers, our number is +1 (610) 640-4207.
Neuronetics Inc executives and other stock owners filed with the SEC include: